Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Ocular disposition of the hemiglutarate ester prodrug of ∆⁹-Tetrahydrocannabinol from various ophthalmic formulations.

Hingorani T, Adelli GR, Punyamurthula N, Gul W, Elsohly MA, Repka MA, Majumdar S.

Pharm Res. 2013 Aug;30(8):2146-56. doi: 10.1007/s11095-013-1072-x. Epub 2013 Jun 5.

2.

Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.

Adelli GR, Bhagav P, Taskar P, Hingorani T, Pettaway S, Gul W, ElSohly MA, Repka MA, Majumdar S.

Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2167-2179. doi: 10.1167/iovs.16-20757.

3.

Effect of ion pairing on in vitro transcorneal permeability of a Δ(9) -tetrahydrocannabinol prodrug: potential in glaucoma therapy.

Hingorani T, Gul W, Elsohly M, Repka MA, Majumdar S.

J Pharm Sci. 2012 Feb;101(2):616-26. doi: 10.1002/jps.22791. Epub 2011 Oct 11.

4.

Enhanced solubility, stability, and transcorneal permeability of δ-8-tetrahydrocannabinol in the presence of cyclodextrins.

Hippalgaonkar K, Gul W, ElSohly MA, Repka MA, Majumdar S.

AAPS PharmSciTech. 2011 Jun;12(2):723-31. doi: 10.1208/s12249-011-9639-5. Epub 2011 Jun 3.

5.

Chemical stability and bioadhesive properties of an ester prodrug of Delta 9-tetrahydrocannabinol in poly(ethylene oxide) matrices: effect of formulation additives.

Thumma S, Majumdar S, ElSohly MA, Gul W, Repka MA.

Int J Pharm. 2008 Oct 1;362(1-2):126-32. doi: 10.1016/j.ijpharm.2008.06.025. Epub 2008 Jul 5.

6.

Preformulation studies of a prodrug of Delta9-tetrahydrocannabinol.

Thumma S, Majumdar S, Elsohly MA, Gul W, Repka MA.

AAPS PharmSciTech. 2008;9(3):982-90. doi: 10.1208/s12249-008-9136-7. Epub 2008 Aug 28.

7.

Influence of plasticizers on the stability and release of a prodrug of Delta(9)-tetrahydrocannabinol incorporated in poly (ethylene oxide) matrices.

Thumma S, ElSohly MA, Zhang SQ, Gul W, Repka MA.

Eur J Pharm Biopharm. 2008 Oct;70(2):605-14. doi: 10.1016/j.ejpb.2008.06.009. Epub 2008 Jun 18.

8.

Ocular Disposition of ∆8-Tetrahydrocannabinol from Various Topical Ophthalmic Formulations.

Punyamurthula NS, Adelli GR, Gul W, Repka MA, ElSohly MA, Majumdar S.

AAPS PharmSciTech. 2017 Aug;18(6):1936-1945. doi: 10.1208/s12249-016-0672-2. Epub 2016 Nov 30.

PMID:
27905004
9.

Transporter targeted gatifloxacin prodrugs: synthesis, permeability, and topical ocular delivery.

Vooturi SK, Kadam RS, Kompella UB.

Mol Pharm. 2012 Nov 5;9(11):3136-46. doi: 10.1021/mp300245r. Epub 2012 Oct 11.

10.

In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.

Rodriguez-Aller M, Kaufmann B, Guillarme D, Stella C, Furrer P, Rudaz S, El Zaoui I, Valamanesh F, Di Tommaso C, Behar-Cohen F, Veuthey JL, Gurny R.

Eur J Pharm Biopharm. 2012 Apr;80(3):544-52. doi: 10.1016/j.ejpb.2011.11.017. Epub 2011 Dec 3.

PMID:
22155591
11.

Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery.

Babizhayev MA.

Drug Dev Ind Pharm. 2008 Oct;34(10):1071-89. doi: 10.1080/03639040801958413 .

PMID:
18777243
12.

Topical delivery of aqueous micellar resolvin E1 analog (RX-10045).

Cholkar K, Gilger BC, Mitra AK.

Int J Pharm. 2016 Feb 10;498(1-2):326-34. doi: 10.1016/j.ijpharm.2015.12.037. Epub 2015 Dec 17.

13.

Diclofenac sodium ion exchange resin complex loaded melt cast films for sustained release ocular delivery.

Adelli GR, Balguri SP, Bhagav P, Raman V, Majumdar S.

Drug Deliv. 2017 Nov;24(1):370-379. doi: 10.1080/10717544.2016.1256000.

PMID:
28165833
14.

Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys.

ElSohly MA, Stanford DF, Harland EC, Hikal AH, Walker LA, Little TL Jr, Rider JN, Jones AB.

J Pharm Sci. 1991 Oct;80(10):942-5.

PMID:
1664466
15.
16.

In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application.

Rodriguez-Aller M, Guillarme D, El Sanharawi M, Behar-Cohen F, Veuthey JL, Gurny R.

J Control Release. 2013 Aug 28;170(1):153-9. doi: 10.1016/j.jconrel.2013.04.019. Epub 2013 May 3.

PMID:
23648835
17.

Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.

Di Tommaso C, Bourges JL, Valamanesh F, Trubitsyn G, Torriglia A, Jeanny JC, Behar-Cohen F, Gurny R, Möller M.

Eur J Pharm Biopharm. 2012 Jun;81(2):257-64. doi: 10.1016/j.ejpb.2012.02.014. Epub 2012 Mar 16.

PMID:
22445900
19.

Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits.

Stella B, Arpicco S, Rocco F, Burgalassi S, Nicosia N, Tampucci S, Chetoni P, Cattel L.

Eur J Pharm Biopharm. 2012 Jan;80(1):39-45. doi: 10.1016/j.ejpb.2011.10.001. Epub 2011 Oct 8.

PMID:
22008147
20.

Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.

Katragadda S, Gunda S, Hariharan S, Mitra AK.

Int J Pharm. 2008 Jul 9;359(1-2):15-24. doi: 10.1016/j.ijpharm.2008.03.015. Epub 2008 Mar 22.

Supplemental Content

Support Center